SEC Form 5

 \Box

FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response: 1.0

Form 3 Holdings	Reported.		o million m			hours per respo	onse:	1.0
X Form 4 Transact	ions Reported.	File	d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940					
SINGER DA	(First) THERAPEUTICS	(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT] 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2007	(Check a X	onship of R II applicabl Director Officer (giv below)		n(s) to Issuer 10% Owner Other (spec below)	
149 COMMON (Street) MENLO PARK (City)	CA (State)	94025 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X	Form filed	t/Group Filing ((by One Report by More than C	ing Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Act Of (D) (Instr. 3, 4	quired (A) and 5)	or Disposed	5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct	7. Nature of Indirect Beneficial
	(Month/Day/Year) 8)		8)	Amount (A) or (D) Price		Issuer's Fiscal Year (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock	12/17/2007		G4	6,666	D	\$0	725,001	D	
Common Stock	12/17/2007		G4	6,666	D	\$0	718,335	D	
Common Stock	12/17/2007		G4	6,666	D	\$0	711,669	D	
Common Stock							10,166	I	Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Elliot Byrd Singer ⁽¹⁾
Common Stock							6,666	I	Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Emma S Singer ⁽¹⁾
Common Stock							50,166	I	Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Kapp S Singer ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. 3. Transaction Date (Month/Day/Year) 34. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instrumentation of Execution Date, if any (Month/Day/Year) 1. Title of Derivative Security 9. Transaction Date (Month/Day/Year) 34. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instrumentation of Execution Date, if any (Month/Day/Year)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5) Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
---	--	---	--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	puts, calls 4. Transaction Code (Instr.	rities Acquired, Disposed , warrants, options, conve Date Expiration GANumb (D) Extension Date (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		CONVERTI Expiration State and te	Onvertible securitias spiration of adde and 7itletle and Shares Amount of securities		8. Price of 9 Derivative c Security 5 (Instr. 5) E F F	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Dete	Evaluation		Amount or Number				
Stock Option (right to buy)	\$2.7	12/19/2007	A	(A) 15,000	(D)	Date Exercisable (2)	Expiration Date 12/19/2017	Title ⁻Common⁻ Stock	of Shares 15,000	\$0.00	15,000	D	

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

2. 1/12th of the shares subject to the option vest monthly measured from June 11, 2007, such that 100% of the shares subject to the option will be fully vested and exercisable on June 11, 2008

 /s/ Joseph K. Belanoff, CEO of

 Corcept Therapeutics
 02/13/2008

 Incorporated attorney-in-fact

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER of ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Joseph K. Belanoff, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2)
execute for and on behalf of the undersigned, in the
undersigned's capacity as a Director of Corcept Therapeutics Incorporated (the
"Company"), Forms 3, 4, and 5 and any amendments thereto in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney - -in-fact on behalf of the

undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming,

nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of February, 2008.

Signature:

&nbs

p;

/s/ David B. Singer DAVID B. SINGER